GEN Exclusives

More »

GEN News Highlights

More »
Feb 13, 2013

Agilent and Sera Partner to Develop Proteomic Assays for Fetal and Maternal Health

  • Agilent Technologies and Sera Prognostics, a women’s health company, entered a partnership to develop proteomic assays for the early prediction of pregnancy complications. Sera Prognostics is currently developing a test for the early prediction of preterm birth risk using advanced proteomic science.

    “By providing pivotal information to physicians, Sera’s preterm birth predictor is designed to address an unmet medical need for a reliable, early risk assessment that has the potential to help significantly improve the health of mothers and newborns, while materially reducing the costs of care,” said Gregory C. Critchfield, M.D., chairman and CEO of Sera Prognostics.

    As part of the partnership, Sera Prognostics purchased multiple Agilent 1290 Infinity ultrahigh-performance liquid chromatography systems, 6490 iFunnel triple quadrupole mass spectrometry systems, and 1260 Infinity LC systems with ultraviolet detectors and is adapting Agilent’s automated sample-preparation technologies for production.

    The partners will develop high-throughput workflows for sample preparation and mass-spectrometry analysis. To meet the demands of high-volume testing, Sera Prognostics expects to leverage Agilent’s automated sample-prep technology and other automation, including the AssayMAP Bravo and RapidFire fast liquid chromatography together with ultra-sensitive ion funnel triple quadrupole mass spectrometry.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?